Hepatitis C virus (HCV) is the major cause of liver ... there is an increasingly large number of competitive protease inhibitors in development — for example, boceprevir (Schering–Plough ...

Close behind telaprevir is Schering-Plough's (now Merck's) boceprevir, also an HCV-NS3 protease inhibitor. These two oral protease inhibitors remain in phase 3 clinical trials. So far they have ...

hepatitis C virus; mRNA, messenger RNA; PI, protease inhibitor; NS, nonstructural protein; RdRp, RNA-dependent RNA polymerase; —, no drugs in this class in this phase of development.

In the era of DAAs, adherence is paramount to treatment success given the strict dosing regimen of first generation HCV protease inhibitors (PIs). First generation DAAs have high pill burdens and ...

but no prior treatment with an HCV NS3/4A protease inhibitor or NS5A inhibitor; (genotype 3): treat for 16 weeks if previously treated with regimens containing PEG-IFN, ribavirin, and/or ...

May be potentiated by atorvastatin, acetaminophen, ascorbic acid, or CYP3A4 inhibitors (eg, itraconazole, ketoconazole). May be affected by HIV/HCV protease inhibitors, NNRTIs. May antagonize ...